We are live on
!
Find out more
PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$970M
1-Year Est. Return
79.46%
This Fund
S&P 500
This Quarter
Est. Return
+44.88%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$346M
AUM Growth
–
Cap. Flow
+$310M
Cap. Flow
% of AUM
89.56%
Top 10 Holdings %
Top 10 Hldgs %
37.82%
Holding
69
New
69
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$18.9M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$16.3M |
| 3 |
Zimmer Biomet
ZBH
|
+$13.5M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$12.7M |
| 5 |
Boston Scientific
BSX
|
+$11.5M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.87% |
| 2 | Industrials | 0.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Natera
NTRA
$45.1B
| $5.08M | 1.47% |
+150,843
| New | +$5.56M |
|
|
MTEM
27
DELISTED
Molecular Templates, Inc.
MTEM
| $4.78M | 1.38% |
+22,780
| New | +$3.27M |
|
|
ICAD
28
DELISTED
iCAD Inc
ICAD
| $4.67M | 1.35% |
+600,686
| New | +$4.29M |
|
|
AXNX
29
DELISTED
Axonics, Inc. Common Stock
AXNX
| $4.61M | 1.33% |
+166,231
| New | +$3.97M |
|
30
Alnylam Pharmaceuticals
ALNY
$29.6B
| $4.03M | 1.16% |
+35,000
| New | +$3.49M |
|
|
MSON
31
DELISTED
Misonix Inc
MSON
| $3.96M | 1.14% |
+212,500
| New | +$3.89M |
|
32
BioCryst Pharmaceuticals
BCRX
$2.64B
| $3.94M | 1.14% |
+1,141,212
| New | +$2.87M |
|
33
Regenxbio
RGNX
$703M
| $3.48M | 1.01% |
+85,000
| New | +$3.36M |
|
34
KORU Medical Systems
KRMD
$159M
| $3.45M | 1% |
+528,572
| New | +$2.58M |
|
|
RETA
35
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.27M | 0.94% |
+16,000
| New | +$2.92M |
|
36
Ascendis Pharma A/S
ASND
$16.7B
| $3.2M | 0.92% |
+23,004
| New | +$2.56M |
|
37
Alphatec Holdings
ATEC
$1.45B
| $3.19M | 0.92% |
+450,000
| New | +$2.89M |
|
|
XENT
38
DELISTED
Intersect ENT, Inc
XENT
| $3.13M | 0.9% |
+125,500
| New | +$2.54M |
|
|
FOMX
39
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $3.1M | 0.9% |
+932,141
| New | +$2.96M |
|
40
Halozyme
HALO
$11.6B
| $2.92M | 0.84% |
+165,000
| New | +$2.86M |
|
|
AMRN
41
Amarin Corp
AMRN
$296M
| $2.91M | 0.84% |
+6,784
| New | +$2.58M |
|
42
OrthoPediatrics
KIDS
$633M
| $2.82M | 0.81% |
+60,000
| New | +$2.32M |
|
43
Stereotaxis
STXS
$145M
| $2.81M | 0.81% |
+531,718
| New | +$2.11M |
|
44
BioLife Solutions
BLFS
$1.7B
| $2.69M | 0.78% |
+166,000
| New | +$2.7M |
|
|
RCM
45
DELISTED
R1 RCM Inc. Common Stock
RCM
| $2.67M | 0.77% |
+205,720
| New | +$2.35M |
|
46
Guardant Health
GH
$22.2B
| $2.36M | 0.68% |
+30,250
| New | +$2.18M |
|
|
PVLA
47
Palvella Therapeutics
PVLA
$2.22B
| $2.25M | 0.65% |
+7,769
| New | +$2.15M |
|
48
iRadimed
IRMD
$1.14B
| $2.19M | 0.63% |
+93,500
| New | +$2.18M |
|
49
Aurinia Pharmaceuticals
AUPH
$2.04B
| $2.03M | 0.58% |
+100,000
| New | +$921K |
|
|
GNMK
50
DELISTED
GenMark Diagnostics, Inc
GNMK
| $2.02M | 0.58% |
+420,000
| New | +$2.32M |
|
Similar funds
LOIM
MGCM
JWM
WAM
GHC
SAM
TCCM
UIC
Parkman Healthcare Partners's Q4 2019 Portfolio in Review
Q4 2019 is the first quarter with a 13F filing on record for Parkman Healthcare Partners, which disclosed 69 positions worth $346M. Its ten largest holdings account for 38% of the portfolio.
Its largest position is Merck: 230,560 shares worth $20M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, followed by Industrials.
- Parkman Healthcare Partners's largest Q4 2019 buy was Merck: 230,560 shares worth $20M.
- Parkman Healthcare Partners's ten largest holdings make up 38% of its $346M portfolio in Q4 2019.
- Parkman Healthcare Partners disclosed 69 positions in Q4 2019, its first 13F filing on record.
Based on Parkman Healthcare Partners's 13F filing for Q4 2019, filed 13 Feb 2020.